After a median follow-up of about 10 years, the 114 patients who received ART had a 49% decreased risk of biochemical failure compared with the 159 patients who had the wait-and-see approach. The researchers observed only one grade 3 case of late toxicity in the ART group.
Previous studies also have shown the potential oncologic benefits of ART in this patient population. Yet, the use of ART for patients with pT3 prostate cancer following RP remains controversial.
Continue Reading
Renal & Urology News would like to know the urologists’ view, so please answer the following poll question.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.